vizimpro
pfizer europe ma eeig - dacomitinib monohidrat - carcinom, pulmonar non-celulă mică - agenți antineoplazici - vizimpro, ca monoterapie, este indicat pentru tratamentul de primă linie al pacienților adulți cu avansat local sau metastatic, cancer pulmonar fără celule mici (nsclc) cu receptorul factorului de creștere epidermal (egfr) activarea mutații.
giotrif
boehringer ingelheim international gmbh - afatinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - giotrif ca monoterapie este indicat pentru tratamentul ofepidermal receptorul factorului de creștere (egfr) tki-pacienți adulți netratați anterior cu avansat local sau metastatic non-cancer pulmonar cu celule mici (nsclc), cu activarea mutatie egfr(s);nsclc local avansat sau metastatic de histologie scuamoase progresează la sau după chimioterapie pe bază de platină.
carbamazepina lph 200 mg
labormed pharma s.a. - romania - carbamazepinum - compr. - 200mg - antiepileptice derivati de carboxamida
carbamazepina slavia 200 mg
slavia pharm s.r.l. - romania - carbamazepinum - compr. - 200mg - antiepileptice derivati de carboxamida
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agenți antineoplazici - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - medicamente antineoplazice - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - blocaj blocant - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - inversarea blocadei neuromusculare indusă de rocuroniu sau vecuroniu. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex terapia 100 mg/ml
synthon hispania, s.l. - spania - sugammadexum - sol. inj. - 100mg/ml - alte preparate terapeutice preparate antidot